Overview

  • Product nameAnti-PTEN antibody [Y184]
    See all PTEN primary antibodies
  • Description
    Rabbit monoclonal [Y184] to PTEN
  • SpecificityA 42kDa band is seen for some samples in addition to 50-54kDa band- we do not know the specificity of this band. For example Rat kidney, heart, spleen have bands around 50kDa but rat PC-12 cells have single band at ~42kDa.
  • Tested applicationsFlow Cyt, IHC-P, ICC/IF, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human PTEN aa 350 to the C-terminus (C terminal).
    (Peptide available as ab157804)

  • Positive control
    • MCF7, Hela cell lysates, human thyroid gland carcinoma
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

     

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated ‘PUR’ on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    Alternative versions available:

    Anti-PTEN antibody (Alexa Fluor® 488) [Y184] (ab199778)

    Anti-PTEN antibody (HRP) [Y184] (ab199545)

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab32199 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use at an assay dependent concentration. PubMed: 20008304

ab172730-Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.

IHC-P Use at an assay dependent concentration. PubMed: 20199355
ICC/IF Use at an assay dependent concentration.
WB 1/10000. Detects a band of approximately 54 kDa (predicted molecular weight: 47 kDa).Can be blocked with PTEN peptide (ab157804).

For unpurified, use 1/500.

Target

  • FunctionTumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability.
  • Tissue specificityExpressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.
  • Involvement in diseaseDefects in PTEN are a cause of Cowden disease (CD) [MIM:158350]; also known as Cowden syndrome (CS). CD is an autosomal dominant cancer predisposition syndrome associated with elevated risk for tumors of the breast, thyroid and skin. The predominant phenotype for CD is multiple hamartoma syndrome, in many organ systems including the breast (70% of CD patients), thyroid (40-60%), skin, CNS (40%), gastrointestinal tract. Affected individuals are at an increased risk of both breast and thyroid cancers. Trichilemmomas (benign tumors of the hair follicle infundibulum), and mucocutaneous papillomatosis (99%) are hallmarks of CD.
    Defects in PTEN are the cause of Lhermitte-Duclos disease (LDD) [MIM:158350]; also known as cerebelloparenchymal disorder VI. LDD is characterized by dysplastic gangliocytoma of the cerebellum which often results in cerebellar signs and seizures. LDD and CD seem to be the same entity, and are considered as hamartoma-neoplasia syndromes.
    Defects in PTEN are a cause of Bannayan-Zonana syndrome (BZS) [MIM:153480]; also known as Ruvalcaba-Myhre-Smith syndrome (RMSS) or Bannayan-Riley-Ruvalcaba syndrome (BRRS). In BZS there seems not to be an increased risk of malignancy. It has a partial clinical overlap with CD. BZS is characterized by the classic triad of macrocephaly, lipomatosis and pigmented macules of the gland penis.
    Defects in PTEN are a cause of head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck.
    Defects in PTEN are a cause of susceptibility to endometrial cancer [MIM:608089].
    Note=PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.
    Defects in PTEN are a cause of susceptibility to glioma type 2 (GLM2) [MIM:613028]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas.
    Defects in PTEN are a cause of VACTERL association with hydrocephalus (VACTERL-H) [MIM:276950]. VACTERL is an acronym for vertebral anomalies, anal atresia, congenital cardiac disease, tracheoesophageal fistula, renal anomalies, radial dysplasia, and other limb defects.
    Defects in PTEN may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
    Defects in PTEN are a cause of macrocephaly/autism syndrome (MCEPHAS) [MIM:605309]. Patients have autism spectrum disorders and macrocephaly, with head circumferences ranging from +2.5 to +8 SD for age and sex (average head circumference +4.0 SD).
    Note=A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.
  • Sequence similaritiesContains 1 C2 tensin-type domain.
    Contains 1 phosphatase tensin-type domain.
  • DomainThe C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.
  • Post-translational
    modifications
    Phosphorylated in vitro by MAST1, MAST2 and MAST3. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4.
    Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN comportmentalization.
  • Cellular localizationCytoplasm. Nucleus. Nucleus > PML body. Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies.
  • Information by UniProt
  • Database links
  • Alternative names
    • 10q23del antibody
    • BZS antibody
    • DEC antibody
    • GLM2 antibody
    • MGC11227 antibody
    • MHAM antibody
    • MMAC1 antibody
    • MMAC1 phosphatase and tensin homolog deleted on chromosome 10 antibody
    • Mutated in multiple advanced cancers 1 antibody
    • Phosphatase and tensin homolog antibody
    • Phosphatase and tensin like protein antibody
    • Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN antibody
    • Pten antibody
    • PTEN_HUMAN antibody
    • PTEN1 antibody
    • TEP1 antibody
    see all

Anti-PTEN antibody [Y184] images

  • All lanes : Anti-PTEN antibody [Y184] (ab32199) at 1/10000 dilution (purified)

    Lane 1 : brain lysate
    Lane 2 : brain lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Anti-rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size : 47 kDa
    Observed band size : 54 kDa (why is the actual band size different from the predicted?)

    Blocking buffer: 5% NFDM/TBST
    Dilution buffer: 5% NFDM/TBST

  • All lanes : Anti-PTEN antibody [Y184] (ab32199) at 1/10000 dilution (purified)

    Lane 1 : MCF7 whole cell lysate
    Lane 2 : HEK293 whole cell lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    Anti-rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

    Predicted band size : 47 kDa
    Observed band size : 54 kDa (why is the actual band size different from the predicted?)

    Blocking buffer: 5% NFDM/TBST
    Dilution buffer: 5% NFDM/TBST



  • Predicted band size : 47 kDa

    Lanes 1, 3 and 5: PTEN knockout HAP1 cell lysate (20 µg)

    Lanes 2, 4 and 6: Wild-type HAP1 cell lysate (20 µg)

    Lanes 1 and 2: Green signal from target – ab32199 observed at 47 kDa

    Lanes 3 and 4: Red signal from loading control – ab8245 observed at 37 kDa

    Lanes 5 and 6: Merged (red and green) signal

    ab32199 was shown to recognize PTEN when PTEN knockout samples were used, along with additional cross-reactive bands. Wild-type and PTEN knockout samples were subjected to SDS-PAGE. ab32199 and ab8245 (loading control to GAPDH) were diluted to 1/500 and 1/2000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.

  • Anti-PTEN antibody [Y184] (ab32199) at 1/500 dilution (Unpurified) + MCF7 cell lysate

    Predicted band size : 47 kDa
    Observed band size : 54 kDa (why is the actual band size different from the predicted?)
  • All lanes : Anti-PTEN antibody [Y184] (ab32199) at 1/500 dilution (Unpurified)

    Lane 1 : Mouse primary bone marrow derived macrophage whole cell lysate
    Lane 2 : Mouse primary bone marrow derived macrophage whole cell lysate
    Lane 3 : Mouse primary bone marrow derived macrophage whole cell lysate
    Lane 4 : Mouse primary bone marrow derived macrophage whole cell lysate

    Lysates/proteins at 50 µg per lane.

    Secondary
    HRP-conjugated goat anti-rabbit IgG polyclonal
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 47 kDa
    Observed band size : 50 kDa (why is the actual band size different from the predicted?)


    Exposure time : 30 seconds

    This image is courtesy of an anonymous Abreview

    Treatment:

    Lane 1 - control siRNA 24 hours

    Lane 2 - PTEN siRNA 24 hours

    Lane 3 - control siRNA 48 hours

    Lane 4 - PTEN siRNA 48 hours

    See Abreview

References for Anti-PTEN antibody [Y184] (ab32199)

This product has been referenced in:
  • Ma J  et al. microRNA-22 attenuates neuronal cell apoptosis in a cell model of traumatic brain injury. Am J Transl Res 8:1895-902 (2016). WB ; Rat . Read more (PubMed: 27186313) »
  • Liao HF  et al. DNMT3L promotes quiescence in postnatal spermatogonial progenitor cells. Development 141:2402-13 (2014). Read more (PubMed: 24850856) »

See all 17 Publications for this product

Product Wall

Application Western blot
Sample African Green Monkey Cell lysate - whole cell (COS7)
Gel Running Conditions Reduced Denaturing
Loading amount 10 µg
Specification COS7
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted Oct 20 2015

Application Western blot
Sample Dog Cell lysate - whole cell (Madin-Darby canine kidney (MDCK) cell)
Gel Running Conditions Reduced Denaturing
Loading amount 10 µg
Specification Madin-Darby canine kidney (MDCK) cell
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted Oct 02 2015

Application Western blot
Sample Cow Cell lysate - whole cell (Bovine aortic endothelial cell)
Gel Running Conditions Reduced Denaturing
Loading amount 10 µg
Specification Bovine aortic endothelial cell
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted Sep 25 2015

Application Western blot
Sample Rat Cell lysate - whole cell (RBL-2H3 cell)
Gel Running Conditions Reduced Denaturing
Loading amount 10 µg
Specification RBL-2H3 cell
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted Sep 08 2015

Application Western blot
Sample Human Cell lysate - whole cell (HEK293T cells)
Gel Running Conditions Reduced Denaturing
Loading amount 10 µg
Specification HEK293T cells
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
Username

Abcam user community

Verified customer

Submitted Jun 15 2015

Application Western blot
Loading amount 50 µg
Gel Running Conditions Reduced Denaturing
Sample Mouse Cell lysate - whole cell (Primary bone marrow derived macrophage)
Specification Primary bone marrow derived macrophage
Treatment siRNA
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted May 28 2014

Sure, I'm happy to issue a credit for this. Your credit ID number is ***. Please let me know if you need anything else. Have a great weekend!

Thank you for contacting us. ab32199, anti-PTEN [Y184], has been develop to recognise the human PTEN, Uniprot reference P60484 http://www.uniprot.org/uniprot/P60484. ab104517, anti-PTEN1, has been develop to target the human PTEN1 prote...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (Colon cell line)
Loading amount 80 µg
Specification Colon cell line
Gel Running Conditions Reduced Denaturing (3-8%)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 25°C
Username

Abcam user community

Verified customer

Submitted Dec 29 2010

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (Breast cancer cell lines)
Loading amount 20 µg
Specification Breast cancer cell lines
Gel Running Conditions Non-reduced Denaturing
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 4°C
Username

Abcam user community

Verified customer

Submitted Dec 15 2010

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"